Journal of the Neurological Sciences
Volume 223, Issue 2 , Pages 167-178 , 30 August 2004

Leptomeningeal metastasis: survival and prognostic factors in 155 patients

  • Ulrich Herrlinger

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49-7071-2980466; fax: +49-7071-295260.
    • Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany
    • ,
  • Heike Förschler

      Affiliations

    • Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany
    • ,
  • Wilhelm Küker

      Affiliations

    • Department of Neuroradiology, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany
    • ,
  • Richard Meyermann

      Affiliations

    • Institute for Brain Research, University of Tübingen, Calwer Str. 3, D-72076 Tübingen, Germany
    • ,
  • Michael Bamberg

      Affiliations

    • Department of Radiation Oncology, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany
    • ,
  • Johannes Dichgans

      Affiliations

    • Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany
    • ,
  • Michael Weller

      Affiliations

    • Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany

Received 16 January 2004 ,Revised 6 May 2004 ,Accepted 12 May 2004.

References 

  1. Kaplan JG, DeSouza TG, Farkash A, et al.  Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J. Neuro-oncol. 1990;9:225–229
  2. Van Oostenbrugge RJ, Hopman AH, Arends JW, et al.  Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J. Clin. Oncol. 2000;18:2053–2058
  3. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch. Neurol. 1996;53:626–632
  4. Boogerd W, Hart AAM, Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer. 1991;67:1685–1695
  5. Fizazi K, Asselain B, Vincent-Salomon A, et al.  Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer. 1996;77:1315–1323
  6. Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases. Treatment results in 98 consecutive patients. Isr. J. Med. Sci. 1988;24:611–618
  7. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors. Cancer. 1982;49:759–772
  8. Berg S, Balis F, Zimm S, et al.  Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J. Clin. Oncol. 1992;10:143–148
  9. Blaney SM, Heideman R, Berg S, et al.  Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J. Clin. Oncol. 2003;21:143–147
  10. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002;94:2675–2680
  11. Glantz MJ, Jaeckle KA, Chamberlain MC, et al.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999;5:3394–3402
  12. Glantz MJ, Jaeckle KA, Chamberlain MC, et al.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 1999;17:3110–3116
  13. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J. Clin. Oncol. 1993;11:561–569
  14. Jaeckle KA, Phuphanich S, Bent MJ, et al.  Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br. J. Cancer. 2001;84:157–163
  15. Jaeckle KA, Batchelor T, O'Day SJ, et al.  An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neuro-oncol. 2002;57:231–239
  16. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–1763
  17. Glantz MJ, Cole BF, Recht L, et al.  High-dose intravenous methotrexate for patients with nonleukemic cancer: is intrathecal chemotherapy necessary?. J. Clin. Oncol. 1998;16:1561–1567
  18. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch. Neurol. 1981;38:696–699
  19. Morra E, Lazzarino M, Brusamolino E, et al.  The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Cancer. 1993;72:439–445
  20. Schabet M, Kloeter I, Adam T, et al.  Diagnosis and treatment of meningeal carcinomatosis in 10 patients with breast cancer. Eur. Neurol. 1986;25:403–411
  21. Weller M, Stevens A, Sommer N, et al.  Tumor cell dissemination triggers an intrathecal immune response in neoplastic meningitis. Cancer. 1992;69:1475–1480
  22. Weller M, Stevens A, Sommer N, et al.  Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia. Acta Neurol. Scand. 1992;86:129–133
  23. Weller M, Stevens A, Sommer N, Wiethölter H. Intrathecal IgM response in disseminated cerebrospinal metastasis from malignant melanoma. J. Neuro-oncol. 1993;16:55–59
  24. Herrlinger U, Schabet M, Brugger W, et al.  Primary CNS lymphoma 1991–1997: outcome and late adverse effects after combined modality treatment. Cancer. 2001;91:130–135
  25. Herrlinger U, Schabet M, Brugger W, et al.  German Cancer Society Neuro-Oncology Working group NOA-03 multi-center trial of single agent high-dose methotrexate for primary CNS lymphoma. Ann. Neurol. 2002;51:247–252
  26. Herrlinger U, Brugger W, Bamberg M, Küker W, Dichgans J, Weller M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology. 2000;54:1707–1708
  27. Herrlinger U, Küker W, Platten M, et al.  First-line therapy with temozolomide induces complete response in primary CNS lymphoma. Neurology. 2002;58:1573–1574
  28. Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. J. Am. Stat. Assoc. 1958;53:457–481
  29. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 1992;10:635–643
  30. Arita N, Taneda M, Hayakawa T. Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir. 1994;126:84–92
  31. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch. Neurol. 1994;51:457–461
  32. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J. Clin. Oncol. 1987;5:1655–1662
  33. Kim M. Intracranial involvement by metastatic advanced gastric carcinoma. J. Neuro-oncol. 1999;43:59–62
  34. Espat NJ, Bilsky M, Lewis JJ, et al.  Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients. Cancer. 2002;94:2706–2711
  35. Khalil AM, Yamout BI, Tabbal SD, et al.  Case report and review of literature: leptomeningeal relapse in epithelial ovarian cancer. Gynecol. Oncol. 1994;54:227–231
  36. Akintola-Ogunremi O, Whitney C, Mathur SC, et al.  Chronic lymphocytic leukemia presenting with symptomatic central nervous system involvement. Ann. Hematol. 2002;81:402–404
  37. Brick WG, Majmundar M, Hendricks LK, et al.  Leukemic leptomeningeal involvement in stage 0 and stage 1 chronic lymphocytic leukemia. Leuk. Lymphoma. 2002;43:199–201
  38. Cramer SC, Glaspy JA, Efird JT, Louis DN. Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology. 1996;46:19–25
  39. Rhodes CH, Glantz MJ, Glantz L, et al.  A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer. 1996;77:543–548
  40. Storch-Hagenlocher B, Haas J, Vogt-Schaden ME, et al.  Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Ann. Neurol. 2000;47:211–217
  41. Balmaceda C, Gaynor JJ, Sun M, et al.  Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann. Neurol. 1995;38:202–209
  42. Fouladi M, Gajjar A, Boyett JM, et al.  Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J. Clin. Oncol. 1999;17:3234–3237
  43. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol. 1995;38:51–57
  44. Paakko E, Patronas NJ, Schellinger D. Meningeal Gd-DTPA enhancement in patients with malignancies. J. Comput. Assist. Tomogr. 1990;14:542–546
  45. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J. Neuro-Oncol. 1998;38:135–140
  46. Joyson GC, Howell A, Harris M, et al.  Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer. 1994;74:3135–3141
  47. Chamberlain MC, Kormanik PA. Non-AIDS-related lymphomatous meningitis: combined modality therapy. Neurology. 1997;49:1728–1731
  48. Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC101 for the treatment of leptomeningeal metastases. Arch. Neurol. 1995;52:912–917
  49. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994;44:1463–1469
  50. Obbens EAMT, Leavens ME, Beal JW, Lee Y. Ommaya reservoir in 387 cancer patients: a 15-year experience. Neurology. 1985;35:1274–1278
  51. Sandberg DI, Bilsky MH, Souweidane MM, et al.  Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery. 2000;47:49–54
  52. Antonadou D, Paraskevaidis M, Sarris G, et al.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 2002;20:3644–3650
  53. Cairncross JG, Macdonald D, Ludwin S, et al.  Chemotherapy for anaplastic oligodendroglioma. J. Clin. Oncol. 1994;2:2013–2021
  54. Chamberlain MC, Levin VA. Primary central nervous system lymphoma: a role for adjuvant chemotherapy. J. Neuro-Oncol. 1992;14:271–275
  55. Yung WKA, et al.  for the Temodal Brain Tumor Group   Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol. 1999;17:2762–2771
  56. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med. 2001;345:621–622
  57. Paul MJ, Summers Y, Calvert AH, et al.  Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002;12:175–178
  58. Stewart DJ, Maroun JA, Hugenholtz H, et al.  Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thiotepa for meningeal involvement by malignancies. J. Neuro-Oncol. 1987;5:315–322
  59. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003;97:3053–3060

PII: S0022-510X(04)00167-4

doi: 10.1016/j.jns.2004.05.008

Journal of the Neurological Sciences
Volume 223, Issue 2 , Pages 167-178 , 30 August 2004

Article Tools

* Image Usage & Resolution